The role of Autophagy through P140/Lupuzor™ peptide
Autophagy is a central process by which cells recycle valuable components of large biological molecules and organelles to be reused in the synthesis of new proteins. Enzymes help to degrade unused or misfolded and damaged (dysfunctional) compounds within the cell and then participate in rebuilding new compounds. This natural process is essential for the renewal and maintenance of cellular integrity of cells in situations of stress or in the case of infection.
A shift in treating auto-immune disease
Prof. Sylviane Muller’s research is based on a synthetically produced peptide. Previous immunosuppressant drugs functioned by suppressing over-stimulated “B-cells”, key activators of large parts of the body’s immune responses. In a completely new departure, Muller’s P140 peptide takes action further upstream in the immune response. It specifically shuts down so-called CD4 T-cells before they can aggravate the B-cells that cause Lupus.
This targeted approach marks a paradigm shift in treating autoimmune disease. Instead of shutting down otherwise healthy immune responses the T-cells are suppressed leaving the immune system modified but intact.
Autophagy represents a key pathway
Autophagy represents a key pathway that is targeted by the P140/Lupuzor™ peptide. Defects in this complex process underlie many types of diseases, including autoimmune, many inflammatory diseases, and degenerative neurological illnesses (e.g. Parkinson’s and Alzheimer’s diseases), and aging. Thus, therapeutic agents such as P140/Lupuzor™, are unique molecules that may significantly slow down or correct the course of such diseases and considerably improve the quality of the life of patients.
Forigerimod/PI40 targeting major auto-immune disease indications
ImmuPharma together with Professor Sylviane Muller, Lupuzor’s inventor, have presented new evidence supporting Lupuzor’s™ Forigerimod / P140 peptide activity in several other major auto-immune disease indications outside of Lupus including Asthma, CIDP, Rheumatoid Arthritis and Crohn’s Disease. In particular, the peptide appears to have general effects against chronic inflammatory indications. Other pre-clinical evidence supports the molecule’s use in: Neuropsychiatric lupus (NPSLE); and Gougerot-Sjögren syndrome (GSS).
Click here for more information.